Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer*
暂无分享,去创建一个
S Ted Treves | Abass Alavi | Frederick D. Grant | Royal T. Davis | Frederick D Grant | Frederic H Fahey | A. Alavi | S. Treves | F. Fahey | A. Packard | F. Grant | Royal T Davis | Alan B Packard
[1] David A Mankoff,et al. PET imaging of cellular proliferation. , 2005, Radiologic clinics of North America.
[2] C. Ling,et al. On measuring hypoxia in individual tumors with radiolabeled agents. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] M. Blau,et al. 18 F-fluoride for bone imaging. , 1972, Seminars in nuclear medicine.
[4] W. Weber. Positron emission tomography as an imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Dai-ichi Nuclear Accident,et al. The International Commission on Radiological Protection , 1963, Nature.
[6] G. Semenza,et al. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. , 2001, Trends in molecular medicine.
[7] H. Minn,et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography , 2000, European Journal of Nuclear Medicine.
[8] Wei Chen,et al. Advances in evaluation of primary brain tumors. , 2008, Seminars in nuclear medicine.
[9] Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. , 2002, AJR. American journal of roentgenology.
[10] Roland Bares,et al. Hypoxia-imaging with 18F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer , 2007 .
[11] A. Wolf,et al. Absolute Cross Sections for the Production of 18F via the 18O(p, n)18F Reaction , 1979 .
[12] D. Rosenthal. Radiologic diagnosis of bone metastases , 1997, Cancer.
[13] B. Långström,et al. Rapid bone and blood flow formation in impacted morselized allograftsPositron emission tomography (PET) studies on allografts in 5 femoral component revisions of total hip arthroplasty , 2003, Acta orthopaedica Scandinavica.
[14] Chinyere N. Onyebuchi,et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. , 2003, Seminars in oncology.
[15] Daniela Thorwarth,et al. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. , 2007, International journal of radiation oncology, biology, physics.
[16] R. Wootton. The single-passage extraction of 18F in rabbit bone. , 1986, Clinical science and molecular medicine.
[17] J. Barrio,et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] G. Bormans,et al. Measurement of skeletal flow with positron emission tomography and 18F-fluoride in femoral head osteonecrosis , 1998, Archives of Orthopaedic and Trauma Surgery.
[19] H. Schirrmeister,et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] Jean Charles Gilbert,et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] R. Fisher,et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Kohlfuerst,et al. The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[23] P. Price,et al. Positron emission tomography imaging of cell proliferation in oncology. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).
[24] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[25] A. Fischman,et al. Flare response in 18F-fluoride ion PET bone scanning. , 2006, AJR. American journal of roentgenology.
[26] T. Mattfeldt,et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[27] M. Anbar,et al. A distribution study of F18-labelled cationic fluorocomplexes in rats , 1962 .
[28] Wei Chen,et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] V. Canzonieri,et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[30] R. Coleman,et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. , 2002, The Journal of urology.
[31] David L. Schwartz,et al. Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.
[32] U. Metser,et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] L. Micheli,et al. Stress fractures in the pediatric athlete. , 1997, Clinics in sports medicine.
[34] M. Blau,et al. Fluorine-18: a new isotope for bone scanning. , 1962, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] I. Fogelman,et al. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. , 2006, Seminars in nuclear medicine.
[36] A. Dirisamer,et al. Positron Emission Tomography/Computed Tomography with F-18-fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5 ng/ml? , 2005, Molecular Imaging and Biology.
[37] A. Murray,et al. Femoral head viability after Birmingham resurfacing hip arthroplasty: assessment with use of [18F] fluoride positron emission tomography. , 2006, The Journal of bone and joint surgery. American volume.
[38] R. Pötter,et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] R. Coleman,et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] A. Jones,et al. Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging. , 1976, Seminars in nuclear medicine.
[41] A. Scott,et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[42] A. Padhani. PET imaging of tumour hypoxia , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.
[43] Thomas Scholbach,et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? , 2007, BMC Cancer.
[44] J. Eary,et al. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[45] S. Larson,et al. 2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy , 2005, Clinical Cancer Research.
[46] Falko Fend,et al. Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma , 2007, Clinical Cancer Research.
[47] Sanz,et al. Positron emission tomography with 18fluorine‐labelled deoxyglucose: utility in localized and advanced prostate cancer , 1999, BJU international.
[48] ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. , 2008, Annals of the ICRP.
[49] S. Berlangieri,et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[50] M. Piert,et al. Allogenic bone graft viability after hip revision arthroplasty assessed by dynamic [18F]fluoride ion positron emission tomography , 1999, European Journal of Nuclear Medicine.
[51] I. Sesterhenn,et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[52] Daniela Thorwarth,et al. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer , 2005, BMC Cancer.
[53] G. Blake,et al. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. , 2001, Seminars in nuclear medicine.
[54] E. Nitzsche,et al. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? , 1998, Radiology.
[55] J. Thrall. Technetium-99m labeled agents for skeletal imaging. , 1976, CRC critical reviews in clinical radiology and nuclear medicine.
[56] G. Blake,et al. Quantitative studies of bone in postmenopausal women using (18)F-fluoride and (99m)Tc-methylene diphosphonate. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] Eyal Mishani,et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[58] Icrp. Radiation dose to patients from radiopharmaceuticals , 1988 .
[59] Reiman,et al. 9:30-9:45. Preliminary Evaluation of F-18 Fluorocholine (FCH) as a PET Tumor Imaging Agent. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[60] T K Lewellen,et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.
[61] P. Ring,et al. Studies on diphosphonate kinetics , 1987, European Journal of Nuclear Medicine.
[62] J. D. Harrison,et al. Radiation Dose to Patients from Radiopharmaceuticals , 1988 .
[63] M. Varia,et al. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. , 2001, International journal of radiation oncology, biology, physics.
[64] S. Wientroub,et al. Back Pain in Adolescents: Assessment With Integrated 18F-Fluoride Positron-emission Tomography-Computed Tomography , 2007, Journal of pediatric orthopedics.
[65] J. S. Laughlin,et al. Kinetics of radionuclides used for bone studies. , 1969, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[66] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[67] J. Thrall,et al. Pharmaceuticals in medical imaging : radiopaque contrast media, radiopharmaceuticals, enhancement agents for magnetic resonance imaging and ultrasound , 1990 .
[68] M. Phelps,et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. , 1993, The Journal of clinical endocrinology and metabolism.
[69] J. Devogelaer,et al. 18F-Fluoride PET for Monitoring Therapeutic Response in Paget’s Disease of Bone , 2005 .
[70] Wei Chen. Clinical Applications of PET in Brain Tumors* , 2007, Journal of Nuclear Medicine.
[71] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[72] R. Huben,et al. The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation. , 1990, The Journal of urology.
[73] M. Bache,et al. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. , 2008, Current medicinal chemistry.
[74] J. M. Arbeit,et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. , 2000, Cancer research.
[75] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[76] M. Schindl,et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. , 2001, Cancer.
[77] Lester J. Peters,et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[78] H. Schirrmeister,et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] Georg A. Becker,et al. Assessment of Porcine Bone Metabolism by Dynamic [18F]Fluoride Ion PET: Correlation with Bone Histomorphometry , 2001 .
[80] T. Block,et al. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy , 1999, European Urology.
[81] Sven Perner,et al. Imaging prostate cancer with 11C-choline PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[82] Klaus Wienhard,et al. Glioma Proliferation as Assessed by 3‘-Fluoro-3’-Deoxy-l-Thymidine Positron Emission Tomography in Patients with Newly Diagnosed High-Grade Glioma , 2008, Clinical Cancer Research.
[83] J. Bading,et al. Imaging of Cell Proliferation: Status and Prospects , 2008, Journal of Nuclear Medicine.
[84] V. Ambrosini,et al. PET in genitourinary tract cancers. , 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[85] Eric O. Aboagye,et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[86] A. Groves,et al. Non-[18F]FDG PET in clinical oncology. , 2007, The Lancet. Oncology.
[87] J. S. Laughlin,et al. Depletion of 18F from blood flowing through bone. , 1970, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[88] J. Moul. Prostate specific antigen only progression of prostate cancer. , 2000, The Journal of urology.
[89] J. Bergh,et al. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT , 1998, Skeletal Radiology.
[90] D. Hedley,et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] T. Hara. 18F-fluorocholine: a new oncologic PET tracer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[92] R. Gittes. Carcinoma of the prostate. , 1991, The New England journal of medicine.
[93] Michael E. Phelps,et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.
[94] J Kotzerke,et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[95] Sadek Nehmeh,et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.
[96] Gig Mageras,et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. , 2008, International journal of radiation oncology, biology, physics.
[97] K L Lindsley,et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.
[98] A. Pupi,et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer , 2008, La radiologia medica.
[99] Gary D Hutchins,et al. A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171 , 2006, Clinical Cancer Research.
[100] D A Hilton,et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.
[101] A. Scott,et al. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. , 2007, Seminars in nuclear medicine.
[102] R. Miralbell,et al. Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[103] N. Shinoura,et al. PET imaging of brain tumor with [methyl-11C]choline. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[104] C. Ling,et al. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. , 2008, Cancer research.
[105] Hubert Vesselle,et al. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. , 2007, Seminars in nuclear medicine.
[106] S. Ametamey,et al. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[107] O. S. Nielsen,et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[108] J R Griffiths,et al. The OxyLite: a fibre-optic oxygen sensor. , 1999, The British journal of radiology.
[109] H. Schirrmeister,et al. F‐18 NaF PET for Detection of Bone Metastases in Lung Cancer: Accuracy, Cost‐Effectiveness, and Impact on Patient Management , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[110] R. Hawkins,et al. Positron Emission Tomography Diagnosis Of Pulmonary Metastases In Osteogenic Sarcoma , 1994, American journal of clinical oncology.
[111] J. Richter,et al. PET and prostate cancer , 2004, World Journal of Urology.
[112] S Ted Treves,et al. Early Experience With Fluorine-18 Sodium Fluoride Bone PET in Young Patients With Back Pain , 2007, Journal of pediatric orthopedics.
[113] J. Kaanders,et al. Mini Symposium: Pet—the Future from Anatomical to Biological Target Volumes: the Role of Pet in Radiation Treatment Planning , 2022 .
[114] S S Gambhir,et al. PET in oncology: will it replace the other modalities? , 1997, Seminars in nuclear medicine.
[115] J. Overgaard,et al. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[116] K. Krohn,et al. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[117] G. V. von Schulthess,et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.
[118] R A Hawkins,et al. Whole body skeletal imaging with [18F]fluoride ion and PET. , 1993, Journal of computer assisted tomography.
[119] G. Blake,et al. Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics , 2001, Nuclear medicine communications.
[120] J. M. Arbeit,et al. Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth , 2000 .
[121] J. Silverman,et al. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. , 1997, AJR. American journal of roentgenology.
[122] Matthias Reimold,et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[123] T. Mattfeldt,et al. Molecular imaging of proliferation in malignant lymphoma. , 2006, Cancer research.
[124] M. Graham,et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[125] F. O’Sullivan,et al. Hypoxia and Glucose Metabolism in Malignant Tumors , 2004, Clinical Cancer Research.